Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Period	PE Ratio
2022-12-31	-9.93
2023-03-31	-57.92
2023-06-30	N/A
2023-12-31	-15.44
2024-12-31	-18.78
2025-12-31	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XERS	$6.95	+0.72%	2.40M
3
4
5

Xeris Biopharma Holdings Inc. (XERS) PE Ratio

PE Ratio Data

Get Xeris Biopharma Holdings Inc. Data in Excel

More XERS Financial Data